News

Age, skin phototype, and personal history of skin cancer are easily captured data elements that could form the basis of a practical, risk-stratified approach to surveillance.

The two conditions can have similar manifestations but differ in prognosis and treatment, which makes an accurate, early diagnosis important.

Survodutide is a dual GLP-1/glucagon receptor agonist that was also able to normalize liver fat in 61% of patients with metabolic dysfunction-associated steatotic liver disease.

Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics.

If prospective studies of clinical outcomes confirm the findings, one near-term application of the research might be using automated analysis of speech samples to monitor patients with schizophrenia.

Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.

In this discussion, Jorge Nieva, M.D., professor of clinical medicine at the University of Southern California Norris Comprehensive Cancer Center, explores how pesticide exposure from otherwise “healthy” diets may help explain the rise of early-onset lung cancer in non-smokers.

The healthcare industry succeeded in making behavioral healthcare more accessible, argues Machinify's Lisa Pincher. Now, it must build the infrastructure to support that care responsibly.

Hofstra University and Northwell Health’s jointly founded medical school has secured funding from the National Institutes of Health for its combined M.D./Ph.D. program.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, says that when used together, the numeric pain score and function scores give clinicians a far more complete clinical picture of a patient’s pain.

If approved, cemdisiran could be the first RNAi therapeutic to treat generalized myasthenia gravis that would be dosed every 12 weeks.

The findings add to the evidence that targeted therapies can improve outcomes in early-stage, oncogene-driven lung cancers, say the study's authors.

An electronic health record–based diabetes risk tool helped primary care teams target prevention and reduce progression to type 2 diabetes in prediabetes patients.

David Blair, CEO of LucyRx, and Jason Borschow, CEO of Abarca, spoke to Managed Healthcare Executive about the company’s merger and how the combined company is positioned for the PBM market of the future.

Skinvive by Juvéderm recently received FDA approval as the first hyaluronic acid injectable indicated for reducing horizontal neck lines, with 74.8% of trial participants achieving clinically significant improvement at one month.

Healthcare leaders need to treat artificial intelligence (AI) adoption as an operating model question, not just a matter of IT staffing.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, argues that function-based tools offer a more equitable and clinically meaningful approach to pain management.

The FDA has expanded Capvaxive approval to include 2- to 17-year-olds at increased risk of pneumococcal disease, making it the only pneumococcal conjugate vaccine approved for this population in the United States.

A CDC-led test-negative case-control study using the VISION network found that the 2024-2025 COVID-19 vaccine reduced the odds of medically attended COVID-19 in adults, with an effectiveness of 26% against emergency department/urgent care encounters, 35% against hospitalization and 41% against critical illness, benefits that held up in older adults and immunocompromised patients but waned over time since vaccination.

The merger is expected to close in the third quarter. Both PBMs will operate as wholly owned subsidiaries of Healthcare Revolution Partners.

Without savings from the 340B Drug Pricing Program as a lifeline, hospitals face service reductions or even closure.

The FDA has approved the sunscreen ingredient bemotrizinol, which blocks both UVA and UVB rays.

Prior authorization and high out-of-pocket costs impact blood cancer patients' access to oral cancer drugs, according to a poster at the 2026 ASCO Meeting.

The FDA has set a target action date of July 29, 2026, for Lytenava to treat patients with wet age-related macular degeneration. Outlook Therapeutics had successfully appealed a complete response letter issued in December 2025.

Things got messy fast after ADA security pulled researchers out of its 2026 conference for passing around an anti-NIH-cuts editorial — cue a walkout, a couple of high-profile resignations and a CEO apology video to try to smooth things over.

The Veterans Affair’s Whole Health approach includes mindfulness, acupuncture, nutritional counseling, and a free app to help patients manage chronic pain.

Researchers analyzing seven oncology therapies found most U.S. commercial plans treat subcutaneous and IV formulations equally, but five payers enforced IV-preferred policies, according to a poster released at the 2026 ASCO meeting.

A fully remote genetic screening program and a multicenter quality improvement initiative both advanced early type 1 diabetes detection.